Published in J Pharmacol Exp Ther on October 01, 2002
Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine (2011) 1.15
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett (2009) 2.17
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol (2012) 2.13
Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther (2008) 1.73
Increased recognition of Powassan encephalitis in the United States, 1999-2005. Vector Borne Zoonotic Dis (2008) 1.59
Identification and characterization of a second novel human erythrovirus variant, A6. Virology (2002) 1.53
Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion (2005) 1.44
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J Med Chem (2008) 1.35
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
Block to the production of full-length B19 virus transcripts by internal polyadenylation is overcome by replication of the viral genome. J Virol (2008) 1.26
A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res (2010) 1.26
Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol (2005) 1.25
The genome of human parvovirus b19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus. J Virol (2009) 1.19
Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett (2008) 1.15
Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest (2010) 1.14
Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos (2008) 1.12
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol (2008) 1.12
Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis (2006) 1.07
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy (2010) 1.04
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol (2010) 1.03
Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J Org Chem (2005) 1.03
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm (2008) 0.99
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem (2010) 0.99
Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos (2011) 0.96
VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology (2008) 0.96
Molecular characterization of the newly identified human parvovirus 4 in the family Parvoviridae. Virology (2011) 0.95
Relationship between gene expression and function of uterotonic systems in the rat during gestation, uterine activation and both term and preterm labour. J Physiol (2008) 0.95
Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther (2013) 0.94
Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org Lett (2003) 0.94
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol (2009) 0.93
Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg Med Chem Lett (2009) 0.93
Successful pregnancy with nocturnal hemodialysis. Am J Kidney Dis (2004) 0.93
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol (2010) 0.91
Simian parvovirus infection: a potential zoonosis. J Infect Dis (2004) 0.91
Reply to Naccache et al: Viral sequences of NIH-CQV virus, a contamination of DNA extraction method. Proc Natl Acad Sci U S A (2014) 0.91
Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res (2005) 0.91
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway. Bioorg Med Chem Lett (2010) 0.91
Proinflammatory cytokines inhibit human placental 11beta-hydroxysteroid dehydrogenase type 2 activity through Ca2+ and cAMP pathways. Am J Physiol Endocrinol Metab (2005) 0.91
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res (2010) 0.91
Vaccination with recombinant Mycobacterium avium subsp. paratuberculosis proteins induces differential immune responses and protects calves against infection by oral challenge. Vaccine (2008) 0.90
Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma. Bioorg Med Chem Lett (2009) 0.89
Parvovirus B19 and onset of juvenile dermatomyositis. JAMA (2005) 0.89
Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos (2012) 0.88
Codon optimization of human parvovirus B19 capsid genes greatly increases their expression in nonpermissive cells. J Virol (2010) 0.88
Metabolites of progesterone and the pregnane X receptor: a novel pathway regulating uterine contractility in pregnancy? Am J Obstet Gynecol (2005) 0.87
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol (2013) 0.86
Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK. J Ocul Pharmacol Ther (2009) 0.85
Bowel dysfunction after transposition of intestinal segments into the urinary tract: 8-year prospective cohort study. J Urol (2007) 0.84
2-Aminobenzimidazoles as potent Aurora kinase inhibitors. Bioorg Med Chem Lett (2009) 0.84
Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica (2011) 0.84
Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci (2002) 0.83
Targeting of lipid-protamine-DNA (LPD) lipopolyplexes using RGD motifs. J Liposome Res (2003) 0.83
Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci (2004) 0.83
An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes. J Pharmacol Toxicol Methods (2012) 0.83
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.82
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem (2014) 0.82
Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine (2011) 0.82
Metabolic stability screen for drug discovery using cassette analysis and column switching. Drug Metab Lett (2007) 0.81
Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries. Pharm Res (2003) 0.81
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg Med Chem Lett (2010) 0.81
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.81
Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther (2002) 0.81
Incorporation of PLGA nanoparticles into porous chitosan-gelatin scaffolds: influence on the physical properties and cell behavior. J Mech Behav Biomed Mater (2011) 0.80
Decreased TCR zeta-chain expression in T cells from patients with acquired aplastic anaemia. Br J Haematol (2007) 0.80
Early toxicology signal generation in the mouse. Toxicol Pathol (2010) 0.80
Discovery and optimization of a series of liver X receptor antagonists. Bioorg Med Chem Lett (2012) 0.79
Human B19 erythrovirus in vitro replication: what's new? J Virol (2008) 0.79
Intraperitoneal infusion of proinflammatory cytokines does not cause activation of the rat uterus during late gestation. Am J Physiol Endocrinol Metab (2005) 0.78
Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. J Pharm Sci (2002) 0.78
Parathyroid hormone-related protein treatment of pregnant rats delays the increase in connexin 43 and oxytocin receptor expression in the myometrium. Biol Reprod (2003) 0.77
Phorbol ester treatment of human myometrial cells suppresses expression of oxytocin receptor through a mechanism that does not involve activator protein-1. Am J Physiol Endocrinol Metab (2006) 0.77
High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis. Drug Metab Lett (2011) 0.77
Inhibitory properties of trapping agents: glutathione, potassium cyanide, and methoxylamine, against major human cytochrome p450 isoforms. Drug Metab Lett (2009) 0.77
Comparison of in vitro-in vivo extrapolation of biliary clearance using an empirical scaling factor versus transport-based scaling factors in sandwich-cultured rat hepatocytes. J Pharm Sci (2013) 0.76
Discovery of a new binding mode for a series of liver X receptor agonists. Bioorg Med Chem Lett (2012) 0.76
Discovery and optimization of a novel Neuromedin B receptor antagonist. Bioorg Med Chem Lett (2009) 0.75
Identification of novel small-molecule Ulex europaeus I mimetics for targeted drug delivery. Bioorg Med Chem (2003) 0.75
Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem Lett (2009) 0.75
Open system gene expression profiling and identification of novel genes for targeted vaccine delivery. Expert Rev Vaccines (2002) 0.75
Automated sample preparation using vapor-phase hydrolysis for amino acid analysis. Anal Biochem (2003) 0.75
Identification and optimization of novel partial agonists of neuromedin B receptor using parallel synthesis. Bioorg Med Chem Lett (2004) 0.75
1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. Drug Metab Dispos (2014) 0.75
On the maintenance of hepatocyte intracellular pH 7.0 in the in-vitro metabolic stability assay. J Pharmacokinet Pharmacodyn (2013) 0.75
Elucidating the Mechanism of Tofacitinib Oxidative Decyanation. Drug Metab Lett (2016) 0.75